Insulet (NASDAQ:PODD) Stock Bumped Up to "Buy" by Wall Street Zen

Key Points

• Wall Street Zen upgraded Insulet from “hold” to “buy,” although the broader analyst consensus remains “hold,” with a consensus price target of $193.48.
• Insulet reported quarterly EPS of $1.66, beating estimates of $1.47, while revenue rose 23.5% year over year to $801.7 million and exceeded forecasts.
• PODD shares opened at $135.28, near the lower end of their 52-week range of $126.40 to $354.88, with the stock’s market capitalization at approximately $9.38 billion.

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently commented on the stock. Stifel Nicolaus cut their price target on shares of Insulet from $225.00 to $180.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Citigroup lifted their price objective on shares of Insulet from $165.00 to $172.00 and gave the company a "neutral" rating in a report on Wednesday, July 8th. TD Cowen lowered their price objective on shares of Insulet from $294.00 to $144.00 and set a "hold" rating for the company in a research report on Thursday, August 6th. Benchmark dropped their target price on shares of Insulet from $250.00 to $185.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Finally, BTIG Research lowered shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $193.48.

Insulet Price Performance

Shares of PODD stock opened at $135.28 on Friday. The stock has a 50 day moving average price of $141.73 and a 200 day moving average price of $159.64. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm has a market capitalization of $9.38 billion, a P/E ratio of 25.29, a P/E/G ratio of 1.06 and a beta of 1.11.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the prior year, the company posted $1.17 EPS. Insulet's quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, sell-side analysts predict that Insulet will post 6.51 earnings per share for the current year.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming grew its stake in Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock worth $60,000 after buying an additional 73 shares during the last quarter. Optas LLC raised its stake in Insulet by 8.8% in the first quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier's stock valued at $222,000 after buying an additional 86 shares during the last quarter. American Trust boosted its holdings in Insulet by 8.6% in the first quarter. American Trust now owns 1,180 shares of the medical instruments supplier's stock worth $248,000 after acquiring an additional 93 shares in the last quarter. Basecamp Wealth Advisors LLC boosted its holdings in Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier's stock worth $66,000 after acquiring an additional 102 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new stake in shares of Insulet during the fourth quarter worth about $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet's product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.